4 active not recruiting, 4 recruiting, 1 approved for marketing, 1 completed. 7 Phase 1, 6 Phase 2, 1 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 7 | Active not recruiting 2, Recruiting 2, Completed 1, Not yet recruiting 1, Terminated 1 |
| Phase 2 | 6 | Active not recruiting 3, Recruiting 3 |
| Phase 3 | 1 | Active not recruiting 1 |
Follow Grade 3b Follicular Lymphoma: new trials by email Literature Review of Grade 3b Follicular Lymphoma trials Research Report on Grade 3b Follicular Lymphoma
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Epcoritamab and Pola-R-mini-CHP for the Treatment of Diffuse Large B Cell Lymphoma in Elderly or Unfit Patients Biospecimen Collection, Computed Tomography, Cyclophosphamide - Diffuse Large B-Cell Lymphoma, Grade 3b Follicular Lymphoma | Phase 1 | Not yet recruiting | Jonsson Comprehensive Cancer Center | 20 | 2026-12-08 | 2026-07-20 |
| A Phase 1/2 Study of UB-VV400 With Rapamycin in Relapsed/Refractory B-cell Malignancies UB-VV400, Rapamycin (sirolimus) - Lymphoma, B Cell, Lymphoma Non-Hodgkin | Phase 1 / Phase 2 | Recruiting | Umoja Biopharma | 274 | 2026-09-01 | 2026-10-09 |
| CD79b-19 CAR T Cells in Non-Hodgkin Lymphoma CD79b-19 CAR T cells, Cyclophosphamide, Fludarabine - Non-hodgkin Lymphoma, Relapsed Non-Hodgkin Lymphoma | Phase 1 | Recruiting | Marcela V. Maus, M.D.,Ph.D. | 24 | 2023-10-26 | 2026-10-09 |
| Study Adding Drugs to Usual Treatment for Large B-Cell Lymphoma That Returned or Did Not Respond to Treatment Biospecimen Collection, Computed Tomography, Lenalidomide - Grade 3b Follicular Lymphoma, High Grade B-Cell Lymphoma | Phase 2 | Recruiting | SWOG Cancer Research Network | 227 | 2023-09-26 | 2025-10-20 |
| Testing Drug Treatments After CAR T-cell Therapy in Patients With Relapsed/Refractory Diffuse Large B-cell Lymphoma Axicabtagene Ciloleucel, Biospecimen Collection, Computed Tomography - Diffuse Large B-Cell Lymphoma, Grade 3b Follicular Lymphoma | Phase 2 | Recruiting | SWOG Cancer Research Network | 396 | 2023-06-12 | 2026-10-15 |
| Acalabrutinib + Liso-Cel In R/R Aggressive B-Cell Lymphomas ACALABRUTINIB, LISOCABTAGENE MARALEUCEL, Lymphodepleting chemotherapy - Refractory Aggressive B-cell Lymphomas, Refractory B-Cell Non-Hodgkin Lymphoma | Phase 2 | Active not recruiting | Patrick C. Johnson, MD | 28 | 2023-03-01 | 2026-01-29 |
| Tafasitamab, Retifanlimab, and Rituximab in Combination With Standard Therapy for the Treatment of Diffuse Large B-cell Lymphoma Bone Marrow Biopsy, Cyclophosphamide, Doxorubicin - Diffuse Large B-Cell Lymphoma, Grade 3b Follicular Lymphoma | Phase 1 / Phase 2 | Active not recruiting | University of Washington | 33 | 2023-01-26 | 2026-06-22 |
| Testing CC-486 (Oral Azacitidine) Plus the Standard Drug Therapy in Patients 75 Years or Older With Newly Diagnosed Diffuse Large B Cell Lymphoma Biospecimen Collection, Computed Tomography, Cyclophosphamide - Ann Arbor Stage III Diffuse Large B-Cell Lymphoma, Ann Arbor Stage IIX (Bulky) Diffuse Large B-Cell Lymphoma | Phase 2 / Phase 3 | Active not recruiting | National Cancer Institute (NCI) | 422 | 2021-05-20 | 2026-10-01 |
| Copanlisib and Combination Chemotherapy for the Treatment of Relapsed or Refractory Diffuse Large B-Cell Lymphoma or Relapsed Grade 3b Follicular Lymphoma Copanlisib, Gemcitabine, Carboplatin - Grade 3b Follicular Lymphoma, Recurrent Diffuse Large B-Cell Lymphoma | Phase 1 | Terminated | University of Washington | 12 | 2020-03-31 | 2023-06-29 |
| Pembrolizumab and Vorinostat in Patients With Relapsed or Refractory DLBCL, FCL or HL. Laboratory Biomarker Analysis, Pembrolizumab, Vorinostat - Grade 3b Follicular Lymphoma, Recurrent B-Cell Lymphoma, Unclassifiable, With Features Intermediate Between DLBCL and Classic HL | Phase 1 | Active not recruiting | City of Hope Medical Center | 52 | 2017-07-18 | 2026-08-21 |
| An Italian Experience on Grade 3b Follicular Lymphoma Grade 3b Follicular Lymphoma | Unknown | A.O.U. Città della Salute e della Scienza | 60 | 2016-10-01 | 2016-10-07 | |
| Pembrolizumab and Combination Chemotherapy in Treating Patients With Previously Untreated Diffuse Large B-cell Lymphoma or Grade 3b Follicular Lymphoma Cyclophosphamide, Doxorubicin Hydrochloride, Laboratory Biomarker Analysis - Composite Lymphoma, Grade 3b Follicular Lymphoma | Phase 1 | Completed | University of Washington | 30 | 2015-11-24 | 2020-10-14 |
| Expanded Access Program for Epcoritamab Epcoritamab - Large B-cell Lymphoma, Diffuse Large B-Cell Lymphoma, Not Otherwise Specified | Approved for marketing | Genmab | 2023-05-25 |
Lymphoma, Large B-Cell, Diffuse (12) · Lymphoma, B-Cell (4) · Lymphoma, Follicular (4) · Lymphoma, Non-Hodgkin (3) · Lymphoma, B-Cell, Marginal Zone (2) · Composite Lymphoma (1) · Lymphoma (1) · Lymphoma, Mantle-Cell (1) · Pyloric Stenosis, Hypertrophic (1)
Hemic and Lymphatic Diseases (12) · Immune System Diseases (12) · Immunoproliferative Disorders (12) · Lymphatic Diseases (12) · Lymphoproliferative Disorders (12) · Neoplasms (12) · Neoplasms by Histologic Type (12) · Lymphoma (11) · Lymphoma, Non-Hodgkin (9) · Lymphoma, B-Cell (8) · Digestive System Diseases (1) · Gastric Outlet Obstruction (1) · Gastrointestinal Diseases (1) · Neoplasms, Complex and Mixed (1) · Pyloric Stenosis (1)
Cyclophosphamide (7) · Magnetic Resonance Spectroscopy (5) · Rituximab (5) · CT-P10 (4) · Doxorubicin (4) · Prednisone (4) · Specimen Handling (4) · Vincristine (3) · deltacortene (3) · fludarabine (3) · polatuzumab vedotin (3) · prednylidene (3) · Disulfides (2) · Hyaluronoglucosaminidase (2) · Immunoglobulins (2)
University of Washington (3) · SWOG Cancer Research Network (2) · A.O.U. Città della Salute e della Scienza (1) · City of Hope Medical Center (1) · Genmab (1) · Jonsson Comprehensive Cancer Center (1) · Marcela V. Maus, M.D.,Ph.D. (1) · National Cancer Institute (NCI) (1) · Patrick C. Johnson, MD (1) · Umoja Biopharma (1)
United States (11)
Alex F Herrera (1) · Barbara Botto, MD (1) · Brian T Hess (1) · Connor Johnson, MD (1) · Elizabeth A Brem (1) · Jennifer E Amengual (1) · Luke Walker, MD (1) · Matthew Frigault, MD (1) · Ryan Lynch (1) · Stephen D. Smith (1) · Stephen Smith (1) · Sven De Vos (1)
PMID 34686472, PMID 37339586, PMID 37470137
U10CA180888 (3), P30CA015704 (1)